Till sidinnehåll
Kunskapsbank för cancervården Till cancercentrum.se


Agathangelidis, A., Vardi, A., Baliakas, P., & Stamatopoulos, K. (2014). Stereotyped B-cell receptors in chronic lymphocytic leukemia. Leuk Lymphoma, 55(10), 2252-2261. doi:10.3109/10428194.2013.879715

Al-Sawaf, O., Zhang, C., Tandon, M., Sinha, A., Fink, A.-M., Robrecht, S., . . . Fischer, K. (2020). Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial. The Lancet Oncology, 21(9), 1188-1200. doi:10.1016/S1470-2045(20)30443-5

Al-Sawaf, O., Zhang, C., Tandon, M., Sinha, A., Fink, A. M., Robrecht, S., . . . Fischer, K. (2020). Fixed-duration venetoclax-obinutuzumab for previously untreated patients with chronic lymphocytic leukemia: Follow-up of efficacy and safety results from the multicenter, open-label, randomized, phase III CLL14 trial. Journal of Clinical Oncology, 38(15_suppl), 8027-8027. doi:10.1200/JCO.2020.38.15_suppl.8027

Baliakas, P., Agathangelidis, A., Hadzidimitriou, A., Sutton, L. A., Minga, E., Tsanousa, A., . . . Stamatopoulos, K. (2015). Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerations. Blood, 125(5), 856-859. doi:10.1182/blood-2014-09-600874

Bergmann, M. A., Goebeler, M. E., Herold, M., Emmerich, B., Wilhelm, M., Ruelfs, C., . . . Hallek, M. J. (2005). Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL Study Group. Haematologica, 90(10), 1357-1364.

Binet, J. L., Auquier, A., Dighiero, G., Chastang, C., Piguet, H., Goasguen, J., . . . Gremy, F. (1981). A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer, 48(1), 198-206.

Bottcher, S., Ritgen, M., Fischer, K., Stilgenbauer, S., Busch, R. M., Fingerle-Rowson, G., . . . Kneba, M. (2012). Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol, 30(9), 980-988. doi:10.1200/jco.2011.36.9348

Brewer, J. D., Habermann, T. M., & Shanafelt, T. D. (2014). Lymphoma-associated skin cancer: incidence, natural history, and clinical management. Int J Dermatol, 53(3), 267-274. doi:10.1111/ijd.12208

Brown, J. R., Hillmen, P., O'Brien, S., Barrientos, J. C., Reddy, N. M., Coutre, S. E., . . . Byrd, J. C. (2018). Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL. Leukemia, 32(1), 83-91. doi:10.1038/leu.2017.175

Byrd, J. C., Brown, J. R., O'Brien, S., Barrientos, J. C., Kay, N. E., Reddy, N. M., . . . Hillmen, P. (2014). Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med, 371(3), 213-223. doi:10.1056/NEJMoa1400376

Byrd, J. C., Furman, R. R., Coutre, S. E., Burger, J. A., Blum, K. A., Coleman, M., . . . O'Brien, S. (2015). Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood, 125(16), 2497-2506. doi:10.1182/blood-2014-10-606038

Chanan-Khan, A., Cramer, P., Demirkan, F., Fraser, G., Silva, R. S., Grosicki, S., . . . Hallek, M. (2016). Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Lancet Oncol, 17(2), 200-211. doi:10.1016/s1470-2045(15)00465-9

Coutre, S. E., Barrientos, J. C., Brown, J. R., de Vos, S., Furman, R. R., Keating, M. J., . . . Zelenetz, A. D. (2015). Management of adverse events associated with idelalisib treatment - expert panel opinion. Leuk Lymphoma, 1-20. doi:10.3109/10428194.2015.1022770

Damle, R. N., Wasil, T., Fais, F., Ghiotto, F., Valetto, A., Allen, S. L., . . . Chiorazzi, N. (1999). Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood, 94(6), 1840-1847.

Dighiero, G., Maloum, K., Desablens, B., Cazin, B., Navarro, M., Leblay, R., . . . Travade, P. (1998). Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia. N Engl J Med, 338(21), 1506-1514.

Dohner, H., Stilgenbauer, S., Benner, A., Leupolt, E., Krober, A., Bullinger, L., . . . Lichter, P. (2000). Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med, 343(26), 1910-1916.

Dohner, H., Stilgenbauer, S., James, M. R., Benner, A., Weilguni, T., Bentz, M., . . . Lichter, P. (1997). 11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis. Blood, 89(7), 2516-2522.

Eichhorst, B., et al. (2014). Paper presented at the ASH Annual Meeting Abstract 2014, San Francisco.

Eichhorst, B., Fink, A.-M., Bahlo, J., Busch, R., Kovacs, G., Maurer, C., . . . Hallek, M. (2016). First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. The Lancet Oncology, 17(7), 928-942. doi:https://doi.org/10.1016/S1470-2045(16)30051-1

Else, M., Cocks, K., Crofts, S., Wade, R., Richards, S. M., Catovsky, D., & Smith, A. G. (2012). Quality of life in chronic lymphocytic leukemia: 5-year results from the multicenter randomized LRF CLL4 trial. Leuk Lymphoma, 53(7), 1289-1298. doi:10.3109/10428194.2011.649479

Eyre, T. A., Kirkwood, A. A., Gohill, S., Follows, G., Walewska, R., Walter, H., . . . Fox, C. P. (2019). Efficacy of venetoclax monotherapy in patients with relapsed chronic lymphocytic leukaemia in the post-BCR inhibitor setting: a UK wide analysis. Br J Haematol, 185(4), 656-669. doi:10.1111/bjh.15802

Fallon, M. J., & Heck, J. N. (2015). Fatal Stevens-Johnson syndrome/toxic epidermal necrolysis induced by allopurinol-rituximab-bendamustine therapy. J Oncol Pharm Pract, 21(5), 388-392. doi:10.1177/1078155214533368

Farooqui, M. Z., Valdez, J., Martyr, S., Aue, G., Saba, N., Niemann, C. U., . . . Wiestner, A. (2015). Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial. Lancet Oncol, 16(2), 169-176. doi:10.1016/s1470-2045(14)71182-9

Fischer, K., Bahlo, J., Fink, A. M., Goede, V., Herling, C. D., Cramer, P., . . . Hallek, M. (2016). Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood, 127(2), 208-215. doi:10.1182/blood-2015-06-651125

Fischer, K., Cramer, P., Busch, R., Bottcher, S., Bahlo, J., Schubert, J., . . . Wendtner, C. M. (2012). Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol, 30(26), 3209-3216. doi:JCO.2011.39.2688 [pii] 10.1200/JCO.2011.39.2688

Fischer, K., Cramer, P., Busch, R., Stilgenbauer, S., Bahlo, J., Schweighofer, C. D., . . . Wendtner, C. M. (2011). Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol, 29(26), 3559-3566. doi:JCO.2010.33.8061 [pii] 10.1200/JCO.2010.33.8061

Folkhälsomyndigheten. (2016). Rekommendationer om pneumocockvaccinationer till riskgrupper. Retrieved from https://www.folkhalsomyndigheten.se/publicerat-material/publikationsarkiv/r/rekommendationer-om-pneumokockvaccination-till-riskgrupper/

Furman, R. R., Sharman, J. P., Coutre, S. E., Cheson, B. D., Pagel, J. M., Hillmen, P., . . . O'Brien, S. M. (2014). Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med, 370(11), 997-1007. doi:10.1056/NEJMoa1315226

Goyal, N. G., Maddocks, K. J., Johnson, A. J., Byrd, J. C., Westbrook, T. D., & Andersen, B. L. (2018). Cancer-Specific Stress and Trajectories of Psychological and Physical Functioning in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia. Ann Behav Med, 52(4), 287-298. doi:10.1093/abm/kax004

Gupta, N., Kavuru, S., Patel, D., Janson, D., Driscoll, N., Ahmed, S., & Rai, K. R. (2002). Rituximab-based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukemia. Leukemia, 16(10), 2092-2095. doi:10.1038/sj.leu.2402676

Hallek, M., Cheson, B. D., Catovsky, D., Caligaris-Cappio, F., Dighiero, G., Dohner, H., . . . Kipps, T. J. (2018). iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood, 131(25), 2745-2760. doi:10.1182/blood-2017-09-806398

Hallek, M., Cheson, B. D., Catovsky, D., Caligaris-Cappio, F., Dighiero, G., Dohner, H., . . . Kipps, T. J. (2008). Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood, 111(12), 5446-5456. doi:10.1182/blood-2007-06-093906

Hallek, M., Fischer, K., Fingerle-Rowson, G., Fink, A. M., Busch, R., Mayer, J., . . . Stilgenbauer, S. (2010). Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet, 376(9747), 1164-1174. doi:10.1016/s0140-6736(10)61381-5

Hallek, M., Wanders, L., Ostwald, M., Busch, R., Senekowitsch, R., Stern, S., . . . Emmerich, B. (1996). Serum beta(2)-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma. Leuk Lymphoma, 22(5-6), 439-447.

Hamblin, A. D., & Hamblin, T. J. (2008). The immunodeficiency of chronic lymphocytic leukaemia. Br Med Bull, 87, 49-62. doi:10.1093/bmb/ldn034

Hamblin, T. J., Davis, Z., Gardiner, A., Oscier, D. G., & Stevenson, F. K. (1999). Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood, 94(6), 1848-1854.

Hansson, L., et al. (2015). Real-World Results on Ibrutinib in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL): Data from 97 Swedish Patients Treated in a Compassionate Use Program. Abstract 1745. . Paper presented at the ASH Annual Meeting, Orlando.

Hartkamp, A., Mulder, A. H., Rijkers, G. T., van Velzen-Blad, H., & Biesma, D. H. (2001). Antibody responses to pneumococcal and haemophilus vaccinations in patients with B-cell chronic lymphocytic leukaemia. Vaccine, 19(13-14), 1671-1677.

Holzner, B., Kemmler, G., Kopp, M., Nguyen-Van-Tam, D., Sperner-Unterweger, B., & Greil, R. (2004). Quality of life of patients with chronic lymphocytic leukemia: results of a longitudinal investigation over 1 yr. Eur J Haematol, 72(6), 381-389. doi:10.1111/j.1600-0609.2004.00233.x

Huang, Y. H., Hsiao, L. T., Hong, Y. C., Chiou, T. J., Yu, Y. B., Gau, J. P., . . . Lee, S. D. (2013). Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. J Clin Oncol, 31(22), 2765-2772. doi:10.1200/jco.2012.48.5938

Jain, N., & O'Brien, S. (2015). Targeted therapies for CLL: Practical issues with the changing treatment paradigm. Blood Rev. doi:10.1016/j.blre.2015.12.002

Jones, J. A., Mato, A. R., Wierda, W. G., Davids, M. S., Choi, M., Cheson, B. D., . . . Byrd, J. C. (2018). Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol, 19(1), 65-75. doi:10.1016/s1470-2045(17)30909-9

Karakosta, M., Delicha, E. M., Kouraklis, G., & Manola, K. N. (2016). Association of various risk factors with chronic lymphocytic leukemia and its cytogenetic characteristics. Arch Environ Occup Health, 71(6), 317-329. doi:10.1080/19338244.2015.1116429

Kath, R., Blumenstengel, K., Fricke, H. J., & Hoffken, K. (2001). Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia. J Cancer Res Clin Oncol, 127(1), 48-54.

Keating, M. J., O'Brien, S., Albitar, M., Lerner, S., Plunkett, W., Giles, F., . . . Kantarjian, H. (2005). Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol, 23(18), 4079-4088.

Kilari, D., Venci, N., Friedberg, J., & Bennett, J. M. (2013). Hemophagocytic lymphohistiocytosis masquerading as progressive chronic lymphocytic leukemia. Leuk Res Rep, 2(1), 4-6. doi:10.1016/j.lrr.2012.10.003

Kutsch, N., Bahlo, J., Byrd, J. C., et al.). The international prognostic index for patients with CLL (CLL-IPI): An international meta-analysis. Abstract #7002. Presented at the American Society of Clinical Oncology 2015 Annual Meeting, Chicago, Illinois, May 30, 2015. .

Lai, G. G., Lim, S. T., Tao, M., Chan, A., Li, H., & Quek, R. (2009). Late-onset neutropenia following RCHOP chemotherapy in diffuse large B-cell lymphoma. Am J Hematol, 84(7), 414-417. doi:10.1002/ajh.21420

Lew, T. E., Anderson, M. A., Lin, V. S., Handunnetti, S. M., Came, N. A., Blombery, P., . . . Seymour, J. F. (2020). Undetectable peripheral blood MRD should be the goal of venetoclax in CLL, but attainment plateaus after 24 months. Blood Adv, 4(1), 165-173. doi:10.1182/bloodadvances.2019000864

Lin, V. S., Lew, T. E., Handunnetti, S. M., Blombery, P., Nguyen, T., Westerman, D. A., . . . Anderson, M. A. (2020). BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax. Blood, 135(25), 2266-2270. doi:10.1182/blood.2020004782

Linet, M., Devesa, S., Morgan, G. (2006). The Leukemias. In Schottenfeld, D., Fraumeni, J.f., Jr editors. Cancer Epidemiology and Prevention. Oxford University Press, 3rd edition, 841-871.

Lowry, L., Smith, P., Qian, W., Falk, S., Benstead, K., Illidge, T., . . . Hoskin, P. (2011). Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial. Radiother Oncol, 100(1), 86-92. doi:S0167-8140(11)00205-2 [pii] 10.1016/j.radonc.2011.05.013

Mansouri, L., Cahill, N., Gunnarsson, R., Smedby, K. E., Tjonnfjord, E., Hjalgrim, H., . . . Rosenquist, R. (2013). NOTCH1 and SF3B1 mutations can be added to the hierarchical prognostic classification in chronic lymphocytic leukemia. Leukemia, 27(2), 512-514. doi:10.1038/leu.2012.307

Marti, G. E., Rawstron, A. C., Ghia, P., Hillmen, P., Houlston, R. S., Kay, N., . . . Caporaso, N. (2005). Diagnostic criteria for monoclonal B-cell lymphocytosis. Br J Haematol, 130(3), 325-332. doi:BJH5550 [pii] 10.1111/j.1365-2141.2005.05550.x

Mato, A. R., Hill, B. T., Lamanna, N., Barr, P. M., Ujjani, C. S., Brander, D. M., . . . Nabhan, C. (2017). Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients. Ann Oncol, 28(5), 1050-1056. doi:10.1093/annonc/mdx031

Mato, A. R., Roeker, L. E., Jacobs, R., Hill, B. T., Lamanna, N., Brander, D., . . . Eyre, T. A. (2020). Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy. Clin Cancer Res, 26(14), 3589-3596. doi:10.1158/1078-0432.Ccr-19-3815

Meki, A., O'Connor, D., Roberts, C., & Murray, J. (2011). Hemophagocytic lymphohistiocytosis in chronic lymphocytic leukemia. J Clin Oncol, 29(24), e685-687. doi:10.1200/jco.2011.35.6139

Montserrat, E., Sanchez-Bisono, J., Vinolas, N., & Rozman, C. (1986). Lymphocyte doubling time in chronic lymphocytic leukaemia: analysis of its prognostic significance. Br J Haematol, 62(3), 567-575.

Moran, M., Browning, M., & Buckby, E. (2007). Nursing guidelines for managing infections in patients with chronic lymphocytic leukemia. Clin J Oncol Nurs, 11(6), 914-924. doi:10.1188/07.cjon.914-924

Moreno, C., Greil, R., Demirkan, F., Tedeschi, A., Anz, B., Larratt, L., . . . Flinn, I. W. (2019). Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol, 20(1), 43-56. doi:10.1016/s1470-2045(18)30788-5

Morrison, E. J., Flynn, J. M., Jones, J., Byrd, J. C., & Andersen, B. L. (2016). Individual differences in physical symptom burden and psychological responses in individuals with chronic lymphocytic leukemia. Ann Hematol, 95(12), 1989-1997. doi:10.1007/s00277-016-2790-z

Mozessohn, L., Chan, K. K., Feld, J. J., & Hicks, L. K. (2015). Hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients receiving rituximab for lymphoma: a meta-analysis. J Viral Hepat, 22(10), 842-849. doi:10.1111/jvh.12402

Munir, T., Brown, J. R., O'Brien, S., Barrientos, J. C., Barr, P. M., Reddy, N. M., . . . Woyach, J. A. (2019). Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol, 94(12), 1353-1363. doi:10.1002/ajh.25638

Nationellt kvalitetsregister för Kronisk lymfatisk leukemi. (2016). Kronisk Lymfatisk Leukemi. Nationell kvalitetsregister Årsrapport nr 3, 2007–2016. Retrieved from http://www.cancercentrum.se/samverkan/cancerdiagnoser/blod-lymfom-myelom/kronisk-lymfatisk-leukemi-kll/kvalitetsregister/

Nieto, W. G., Almeida, J., Romero, A., Teodosio, C., Lopez, A., Henriques, A. F., . . . Orfao, A. (2009). Increased frequency (12%) of circulating chronic lymphocytic leukemia-like B-cell clones in healthy subjects using a highly sensitive multicolor flow cytometry approach. Blood, 114(1), 33-37. doi:10.1182/blood-2009-01-197368

O'Brien, S., Jones, J. A., Coutre, S. E., Mato, A. R., Hillmen, P., Tam, C., . . . Stilgenbauer, S. (2016). Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. Lancet Oncol, 17(10), 1409-1418. doi:10.1016/S1470-2045(16)30212-1

O'Brien, S. M., Lamanna, N., Kipps, T. J., Flinn, I., Zelenetz, A. D., Burger, J. A., . . . Coutre, S. E. (2015). A phase 2 study of idelalisib plus rituximab in treatment-naive older patients with chronic lymphocytic leukemia. Blood, 126(25), 2686-2694. doi:10.1182/blood-2015-03-630947

Olsson, C., Sandin-Bojo, A. K., Bjuresater, K., & Larsson, M. (2015). Patients treated for hematologic malignancies: affected sexuality and health-related quality of life. Cancer Nurs, 38(2), 99-110. doi:10.1097/ncc.0000000000000141

Patel, K., Isufi, I., Kothari, S., Davidoff, A. J., Gross, C. P., & Huntington, S. F. (2020). Cost-Effectiveness of First-Line Ibrutinib versus Third-Line in Patients with Untreated Chronic Lymphocytic Leukemia. Blood. doi:10.1182/blood.2020004922

Peterson, C. (2005). Naturläkemedel - egenvård på egen risk! Fara för okända biverkningar och interaktioner med "vanliga" läkemedel. . Läkartidningen, 44, 3201-3202.

Quinquenel, A., Willekens, C., Dupuis, J., Royer, B., Ysebaert, L., De Guibert, S., . . . Delmer, A. (2015). Bendamustine and rituximab combination in the management of chronic lymphocytic leukemia-associated autoimmune hemolytic anemia: a multicentric retrospective study of the French CLL intergroup (GCFLLC/MW and GOELAMS). Am J Hematol, 90(3), 204-207. doi:10.1002/ajh.23909

Raanani, P., Gafter-Gvili, A., Paul, M., Ben-Bassat, I., Leibovici, L., & Shpilberg, O. (2009). Immunoglobulin prophylaxis in chronic lymphocytic leukemia and multiple myeloma: systematic review and meta-analysis. Leuk Lymphoma, 50(5), 764-772. doi:10.1080/10428190902856824

Rai, K. R., Sawitsky, A., Cronkite, E. P., Chanana, A. D., Levy, R. N., & Pasternack, B. S. (1975). Clinical staging of chronic lymphocytic leukemia. Blood, 46(2), 219-234.

Rawstron, A. C., Bennett, F. L., O'Connor, S. J., Kwok, M., Fenton, J. A., Plummer, M., . . . Hillmen, P. (2008). Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. N Engl J Med, 359(6), 575-583. doi:359/6/575 [pii] 10.1056/NEJMoa075290

Rawstron, A. C., Bottcher, S., Letestu, R., Villamor, N., Fazi, C., Kartsios, H., . . . Ghia, P. (2012). Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL. Leukemia, 27(1), 142-149. doi:leu2012216 [pii] 10.1038/leu.2012.216

Rawstron, A. C., Fazi, C., Agathangelidis, A., Villamor, N., Letestu, R., Nomdedeu, J., . . . Ghia, P. (2016). A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study. Leukemia, 30(4), 929-936. doi:10.1038/leu.2015.313

Reddy, K. R., Beavers, K. L., Hammond, S. P., Lim, J. K., & Falck-Ytter, Y. T. (2015). American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology, 148(1), 215-219; quiz e216-217. doi:10.1053/j.gastro.2014.10.039

Robak, T., Dmoszynska, A., Solal-Celigny, P., Warzocha, K., Loscertales, J., Catalano, J., . . . Moiseev, S. I. (2010). Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol, 28(10), 1756-1765. doi:JCO.2009.26.4556 [pii] 10.1200/JCO.2009.26.4556

Rossi, D., Rasi, S., Spina, V., Fangazio, M., Monti, S., Greco, M., . . . Gaidano, G. (2012). Different impact of NOTCH1 and SF3B1 mutations on the risk of chronic lymphocytic leukemia transformation to Richter syndrome. Br J Haematol, 158(3), 426-429. doi:10.1111/j.1365-2141.2012.09155.x

Rossignol, J., Michallet, A. S., Oberic, L., Picard, M., Garon, A., Willekens, C., . . . Ysebaert, L. (2011). Rituximab-cyclophosphamide-dexamethasone combination in the management of autoimmune cytopenias associated with chronic lymphocytic leukemia. Leukemia, 25(3), 473-478. doi:leu2010278 [pii] 10.1038/leu.2010.278

Royle, J. A., Baade, P. D., Joske, D., Girschik, J., & Fritschi, L. (2011). Second cancer incidence and cancer mortality among chronic lymphocytic leukaemia patients: a population-based study. Br J Cancer, 105(7), 1076-1081. doi:10.1038/bjc.2011.313

Rubin, L. G., Levin, M. J., Ljungman, P., Davies, E. G., Avery, R., Tomblyn, M., . . . Infectious Diseases Society of, A. (2014). 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis, 58(3), e44-100. doi:10.1093/cid/cit684

Sanchez Varela, V., Zhou, E. S., & Bober, S. L. (2013). Management of sexual problems in cancer patients and survivors. Curr Probl Cancer, 37(6), 319-352. doi:10.1016/j.currproblcancer.2013.10.009

Shanafelt, T. D., Bowen, D., Venkat, C., Slager, S. L., Zent, C. S., Kay, N. E., . . . Call, T. G. (2007). Quality of life in chronic lymphocytic leukemia: an international survey of 1482 patients. Br J Haematol, 139(2), 255-264. doi:10.1111/j.1365-2141.2007.06791.x

Shanafelt, T. D., & Kay, N. E. (2007). Comprehensive management of the CLL patient: a holistic approach. Hematology Am Soc Hematol Educ Program, 324-331. doi:10.1182/asheducation-2007.1.324

Shanafelt, T. D., Wang, X. V., Kay, N. E., Hanson, C. A., O'Brien, S., Barrientos, J., . . . Tallman, M. (2019). Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia. N Engl J Med, 381(5), 432-443. doi:10.1056/NEJMoa1817073

Shanafelt, T. D., Witzig, T. E., Fink, S. R., Jenkins, R. B., Paternoster, S. F., Smoley, S. A., . . . Dewald, G. W. (2006). Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia. J Clin Oncol, 24(28), 4634-4641. doi:10.1200/jco.2006.06.9492

Slager, S. L., Benavente, Y., Blair, A., Vermeulen, R., Cerhan, J. R., Costantini, A. S., . . . de Sanjose, S. (2014). Medical history, lifestyle, family history, and occupational risk factors for chronic lymphocytic leukemia/small lymphocytic lymphoma: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr, 2014(48), 41-51. doi:10.1093/jncimonographs/lgu001

Smith, T. J., Bohlke, K., Lyman, G. H., Carson, K. R., Crawford, J., Cross, S. J., . . . Armitage, J. O. (2015). Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol, 33(28), 3199-3212. doi:10.1200/jco.2015.62.3488

Socialdepartementet. Hälso- och sjukvårdslag (1982:763) Retrieved from https://www.riksdagen.se/sv/dokument-lagar/dokument/svensk-forfattningssamling/halso--och-sjukvardslag-1982763_sfs-1982-763

Socialdepartementet. Hälso- och sjukvårdslag (2017:30) 5 kap 7 §. Retrieved from https://www.riksdagen.se/sv/dokument-lagar/dokument/svensk-forfattningssamling/halso--och-sjukvardslag_sfs-2017-30

Socialdepartementet. (2009). SOU 2009:11, En nationell cancerstrategi för framtiden.  Retrieved from http://www.regeringen.se/contentassets/e343b40615eb46b395e5c65ca38d1337/en-nationell-cancerstrategi-for-framtiden-sou-200911

Socialstyrelsen. (2013). Barn som anhöriga: konsekvenser och behov när föräldrar har allvarliga svårigheter, eller avlider. Stockholm.

Stephens, D. M., & Byrd, J. C. (2019). How we manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia. Blood. doi:10.1182/blood-2018-11-846808

Stilgenbauer, S., Eichhorst, B., Schetelig, J., Coutre, S., Seymour, J. F., Munir, T., . . . Wierda, W. G. (2016). Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol, 17(6), 768-778. doi:10.1016/s1470-2045(16)30019-5

Stilgenbauer, S., Eichhorst, B., Schetelig, J., Hillmen, P., Seymour, J. F., Coutre, S., . . . Wierda, W. G. (2018). Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial. J Clin Oncol, 36(19), 1973-1980. doi:10.1200/jco.2017.76.6840

Tam, C. S., O'Brien, S., Plunkett, W., Wierda, W., Ferrajoli, A., Wang, X., . . . Keating, M. J. (2014). Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab). Blood, 124(20), 3059-3064. doi:10.1182/blood-2014-06-583765

Tam, C. S., O'Brien, S., Wierda, W., Kantarjian, H., Wen, S., Do, K. A., . . . Keating, M. J. (2008). Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood, 112(4), 975-980. doi:blood-2008-02-140582 [pii] 10.1182/blood-2008-02-140582

Thompson, P. A., Tam, C. S., O'Brien, S. M., Wierda, W. G., Stingo, F., Plunkett, W., . . . Keating, M. J. (2016). Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood, 127(3), 303-309. doi:10.1182/blood-2015-09-667675

Treleaven, J., Gennery, A., Marsh, J., Norfolk, D., Page, L., Parker, A., . . . Webb, D. (2011). Guidelines on the use of irradiated blood components prepared by the British Committee for Standards in Haematology blood transfusion task force. Br J Haematol, 152(1), 35-51. doi:10.1111/j.1365-2141.2010.08444.x

Tsimberidou, A. M., O'Brien, S., Khouri, I., Giles, F. J., Kantarjian, H. M., Champlin, R., . . . Keating, M. J. (2006). Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation. J Clin Oncol, 24(15), 2343-2351. doi:24/15/2343 [pii] 10.1200/JCO.2005.05.0187

Tsimberidou, A. M., Wen, S., McLaughlin, P., O'Brien, S., Wierda, W. G., Lerner, S., . . . Keating, M. J. (2009). Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma. J Clin Oncol, 27(6), 904-910. doi:10.1200/jco.2008.17.5398

van Dongen, J. J., Lhermitte, L., Bottcher, S., Almeida, J., van der Velden, V. H., Flores-Montero, J., . . . Orfao, A. (2012). EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia, 26(9), 1908-1975. doi:10.1038/leu.2012.120

Wierda, W. G., Seymour, J. F., Roberts, A. W., Puvvada, S., Davids, M. S., Wong, S., . . . Stilgenbauer, S. (2014). A phase 2 open-label study of the efficacy of ABT-199 (GDC-0199) in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) harboring 17p deletion. Journal of Clinical Oncology, 32(15_suppl), TPS7121-TPS7121. doi:10.1200/jco.2014.32.15_suppl.tps7121

Woyach, J. A., Ruppert, A. S., Heerema, N. A., Zhao, W., Booth, A. M., Ding, W., . . . Byrd, J. C. (2018). Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. N Engl J Med, 379(26), 2517-2528. doi:10.1056/NEJMoa1812836

Yri, O. E., Torfoss, D., Hungnes, O., Tierens, A., Waalen, K., Nordoy, T., . . . Kolstad, A. (2011). Rituximab blocks protective serologic response to influenza A (H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment. Blood, 118(26), 6769-6771. doi:10.1182/blood-2011-08-372649

Zelenetz, A. D., Barrientos, J. C., Brown, J. R., Coiffier, B., Delgado, J., Egyed, M., . . . Hillmen, P. (2017). Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol, 18(3), 297-311. doi:10.1016/s1470-2045(16)30671-4

Zenz, T., Eichhorst, B., Busch, R., Denzel, T., Habe, S., Winkler, D., . . . Stilgenbauer, S. (2010). TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol, 28(29), 4473-4479. doi:JCO.2009.27.8762 [pii]. 10.1200/JCO.2009.27.8762

Ännu bättre cancervård - delrapport 8. (2012). Insatser för fler kontaktsjuksköterskor inom cancervården. . Retrieved from https://www.cancercentrum.se/globalassets/patient-och-narstaende/samverkan/delrapport-8_kontaktsjukskoterskor_1310131.pdf

Nästa kapitel
21 Vårdprogramgruppen